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Abstract
AIM
To perform a systematic review and meta-analysis on 
platelet-to-lymphocyte ratio (PLR) as a risk factor for 
post-transplant hepatocellular cancer (HCC) recurrence. 
METHODS
A systematic literature search was performed using 
PubMed. Participants of any age and sex, who underwent 
liver transplantation for HCC were considered following 
these criteria: (1) studies comparing pre-transplant low 
vs high PLR values; (2) studies reporting post-transplant 
recurrence rates; and (3) if more than one study was 
reported by the same institute, only the most recent was 
included. The primary outcome measure was set for HCC 
recurrence after transplantation. 
RESULTS
A total of 5 articles, published between 2014 and 2017, 
fulfilled the selection criteria. As for the quality of the 
reported studies, all the investigated articles presented 
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an overall high quality. A total of 899 cases were 
investigated: 718 cases (80.0%) were males. Three 
studies coming from European countries and one from 
Japan presented HCV as the main cause of cirrhosis. On 
the opposite, one Chinese study presented a greater 
incidence of HBV-related cirrhotic cases. In all the studies 
apart one, the PLR cut-off value of 150 was reported. 
At meta-analysis, high PLR value was associated with a 
significant increase in recurrence after transplantation 
(OR = 3.33; 95%CI: 1.78-6.25; P  < 0.001). A moderate 
heterogeneity was observed among the identified studies 
according to the Higgins I 2 statistic value.
CONCLUSION
Pre-transplant high PLR values are connected with an 
increased risk of post-operative recurrence of hepa-
tocellular cancer. More studies are needed for better 
clarify the biological mechanisms of this results. 
Key words: Recurrence; Inflammation; Hepatocellular 
cancer; Liver transplantation; Platelet-to-lymphocyte 
ratio
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Poor data exist on the role of the inflammatory 
marker platelet-to-lymphocyte ratio (PLR) and hepa-
tocellular cancer (HCC) recurrence after liver trans-
plantation. This is the first systematic review and meta-
analysis specifically investigating the role of PLR in 
the setting of liver transplant for HCC. Pre-transplant 
high PLR values confirmed their utility as predictors of 
recurrence, being connected with a 3.33-fold increased 
risk of post-transplant HCC recurrence. 
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to-lymphocyte ratio in the setting of liver transplantation for 
hepatocellular cancer: A systematic review and meta-analysis. 
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INTRODUCTION
Liver transplantation (LT) represents the best therapy 
for the treatment of hepatocellular cancer (HCC)[1]. 
However, LT represents a scarce resource. As a 
consequence, a careful selection of HCC patients must 
be done preoperatively, with the intent to minimize 
the risk of post-LT recurrence[2] It is, in fact, clear that 
transplanting too advanced tumors is connected with 
a higher risk of poor post-LT outcomes[3]. Moreover, an 
error in the selection process corresponds to a “futile 
transplant”, avoiding to transplant another patient in 
the waiting list[4].
After the introduction of the Milan Criteria (MC) in 
1996, several other scores have been proposed in the 
last decades with the intent to refine the selection of HCC 
patients waiting for LT[5-8]. Apart from tumor morphology, 
also biology has been integrated into prognostic scores 
in the last years: Thus, the markers alpha-fetoprotein 
and des-gamma-carboxy-prothrombin, the radiological 
response after locoregional therapies or the tumor 
behaviour at PET scan have been largely investigated[9-13]. 
Recently, also systemic inflammation has been added 
as a possible value to add in the complex “mainframe” 
of HCC selection[14]. Among the different evaluated 
markers, the neutrophil-to-lymphocyte ratio (NLR) has 
been proposed as the most promising predictor of HCC 
recurrence[15,16]. NLR has been also integrated into several 
scores aimed at better select HCC patients waiting for 
LT[17,18]. However, another less intensely investigated 
ratio, namely the platelet-to-lymphocyte ratio (PLR), has 
also reported interesting results[19,20].
The main aim of the present study is to report a 
systematic review of the literature and a meta-analysis 
focused on investigating the role of PLR in the setting 
of liver transplantation as a useful predictor of HCC 
recurrence. 
MATERIALS AND METHODS
Search strategy
A systematic search was done in relation to relevant 
studies focusing on the role of PLR in HCC patients 
undergoing LT. The search strategy was done in accor-
dance with the Preferred Reporting Items for Systemic 
Reviews and Meta-Analysis (PRISMA) guidelines, 
as well as PRISMA for abstracts[21]. A search of the 
electronic databases MEDLINE-PubMed, Cochrane 
Library and EMBASE was conducted using the following 
research terms: (liver transplant*[tw]) AND (platelet-
to-lymphocyte ratio[tw] OR PLR[tw]). Text word [tw] 
was preferred respect to MeSH words with the intent to 
identify In Process citations. Studies published before 
March 6, 2018, were taken into consideration. 
Screening process
The present qualitative systematic review included a 
priori search criteria of journal articles among adult (age 
≥ 18 years) human patients. Studies were limited to 
the English language. We defined as enrollable all the 
studies based on HCC patients having received LT in 
which pre-operative PLR values were correlated with 
the risk of post-LT HCC recurrence. Investigated time 
to recurrence was set at 5 years after LT. 
Exclusion criteria were: (1) papers lacking sufficient 
details; (2) review articles; (3) nonclinical studies; (4) 
expert opinions; (5) letters; (6) conference summaries; 
and (7) case reports. 
Study selection
Two reviewers (QL and FM) independently screened 
the identified studies and their extracted data. In case 
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of disagreement, the paper was discussed by all the 
authors. 
Quality assessment
Selected studies were reviewed based on the repre-
sentativeness of the study population, comparability of 
cohorts, adequate assessment of outcomes, sufficient 
length of follow-up, adequacy of follow-up, and source 
of study funding. The quality of the papers was assessed 
using the Newcastle-Ottawa Quality Assessment Scale 
(NOS): studies with scores > 6 were defined as high-
quality studies[22].
NOS details of each selected study were reported 
in Table 1. The characteristics coming from each study 
were collected in Table 2. The following features were 
collected: first author’s name, reference number, 
number of patients, patient age, patient gender, waiting 
time duration in months, model for end-stage liver 
disease, underlying liver pathology, the diameter of the 
major lesion and the number of tumors at the moment 
of LT, the MC-OUT status at the moment of LT, AFP 
value ≥ 200 ng/mL, any type of locoregional treatment 
(LRT), the PLR cut-off used in the article, the area under 
the receiver operator curve (ROC) for the diagnosis of 
recurrence, the number of post-LT recurrences and the 
5-year tumor-free survival (TFS). 
Statistical analysis
Different PLR cut-offs were observed among the 
identified studies. TFS end-point in the different studies 
corresponded to 5 years after LT. Summary measures 
were extracted from each study and used to generate 
a pooled odds ratio (OR). Higgins I2 statistic was used 
to assess heterogeneity. Higgins I2 statistic values of 
0%-25%, 25%-50%, and > 50% were considered as 
indicative of homogeneity, moderate heterogeneity, 
and high heterogeneity, respectively. Only the random-
effects model was used, starting from the assumption 
that a common OR was unreliable in the analyzed 
studies due to the broad eligibility criteria and the 
different used PLR cut-off values. OR was considered 
statistically significant when the p-value was < 0.05. OR 
and 95% confidence intervals (CI) > 1 revealed that 
the patients with high PLR values had poor prognoses 
(higher risk of recurrence), whereas a result < 1 had 
the opposite meaning. The analysis was performed 
using OpenMEE software (http://www.cebm.brown.
edu/openmee/index.html).
RESULTS
The selection process of the articles is explained in 
Figure 1.
As for the selection process according to the PRISMA 
guidelines, the various examined databases provided 
a total of 39 articles to screen. After removing the 
duplicates and reading the title and the abstract, 28 
articles were removed. Of the remaining 11 papers, 6 
were not considered eligible after full-text evaluation. 
Two studies coming from Hangzhou China were per-
formed on the same population, so only one of these 
studies was selected for the last analysis[23,24]. 
Eventually, 5 articles were identified, with a total of 
899 investigated cases (Table 2)[24-28]. 
As for the quality of the reported studies, all the 
investigated articles were retrospective cohort studies 
all presenting the excellent NOS value of eight, thus 
reporting the overall high quality of the studies focused 
on this topic (Table 1). 
In the selected series, median/mean age ranged 
49-58 years. As for patient gender, 718 cases (80.0%) 
were males. Three studies coming from European 
countries and one from Japan presented HCV as the 
main reason for underlying cirrhotic liver disease (298/556 
cases; 53.6%). On the opposite, one Chinese study 
presented a greater incidence of HBV-related cirrhotic 
cases (320/343 cases; 93.3%). 
Last radiology before LT was available in only three 
studies, showing a median diameter of the major lesion 
ranging 1.3-2.7 cm and a median single lesion (range 
0-2). MC-OUT status was observed in 309 (34.4) 
patients: interestingly enough, a great discrepancy 
was observed among the reported studies, with one 
series coming from Europe showing no cases exceeding 
the MC, and the study coming from China presenting 
58.0% of MC-OUT individuals. Different AFP cut-offs 
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Table 1  Quality of studies evaluated by the modified Newcastle-Ottawa scale
Ref. Selection Comparability Outcome Quality 
scoreCase 
definition
Representativeness Selection of 
controls
Definition of 
controls
Comparable 
for therapy
Comparable 
for etiology
Assessment 
of outcomes
Integrity of 
follow-up
Xia et al[24] Yes Yes No Yes Yes Yes Yes Yes ★★★★
★★★★
Lai et al[25] Yes Yes No Yes Yes Yes Yes Yes ★★★★
★★★★
Parisi et al[26] Yes Yes No Yes Yes Yes Yes Yes ★★★★
★★★★
Nicolini et al[27] Yes Yes No Yes Yes Yes Yes Yes ★★★★
★★★★
Harimoto et al[28] Yes Yes No Yes Yes Yes Yes Yes ★★★★
★★★★
Lai Q et al . PLR and HCC: A meta-analysis
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0.24), showing a moderate heterogeneity among the 
examined studies (Figure 2).
DISCUSSION
Until now, few data have been reported on the 
predictive role of PLR as a risk factor for HCC recurrence 
after liver transplant. Indeed, only five studies have 
been identified in the present systematic review, 
the first of whom published in 2014[24-28]. However, 
although the number of reported cases is relatively 
limited (n = 899), the biological effect of PLR looks to 
be clear, with a strong correlation between high PLR 
values and a greater risk for recurrence. According to 
the results of the meta-analysis, subjects having pre-
LT high PLR values present a 3.33-fold increased risk of 
experiencing HCC recurrence after LT.  
Interestingly enough, the only study in which the 
PLR failed to be a prognostic tool for recurrence was 
the sole in which only patients meeting the MC were 
transplanted[26]. Such an evidence should represent 
a possible explanation for the observed results. It 
is, in fact, possible that a direct correlation may 
exist between higher PLR values and a progressively 
increasing tumor aggressiveness (i.e., higher AFP and 
greater tumor burden). As a possible confirmation of 
were reported in the studies (200/300/400 ng/mL). 
Also in this case, great discrepancies were observed 
among the study coming from Hangzhou and the other 
ones in terms of cases exceeding the reported threshold 
values (48.1% vs 5.5%-15.8%). When reported, LRT 
were performed in 47.3%-100.0% of cases. 
Specifically investigating the PLR values, the cut-
off of 150 was reported in all the series apart from the 
study from Fukuoka Japan, in which the median value 
of 70.4 was investigated. When the diagnostic power 
of PLR in terms of HCC recurrence was investigated, an 
area under the ROC curve of 0.63-0.70 was observed, 
showing an acceptable-to-good ability of this variable 
to diagnose post-transplant recurrence. A total of 
180 (20.0%) cases exceeded the proposed threshold 
values, with a percentage ranging 7.1%-51.1% in the 
various series. 
Five-year tumor-free survivals were reported in 
four studies. In all of them, patients presenting high 
PLR values had worse results, with a value ranging 
81%-25% respect to the ones reported in patients with 
low PLR values (95%-52%).  
The binary random-effects meta-analysis showed 
a strong relationship between poor TFS and elevated 
PLR values (OR = 3.33, 95%CI: 1.78-6.25; p < 0.001). 
Higgins I2 statistic presented a value = 26.8% (p = 
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Figure 1  PRISMA flowchart of the literature search and study selection. 
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fact, clear that a meta-regression weighted for the 
geographical area, HCV vs HBV as the main cause of 
liver failure, living-donor vs deceased-donor LT, and 
markers of tumor aggressiveness should represent a 
more accurate way for better clarify the role of PLR 
in this setting. Unfortunately, the limited number of 
cases reported did not consent us to perform more 
sophisticated analyses. Secondly, no information was 
reported in the different series on the presence and 
grade of portal hypertension, a very well known cause 
of thrombocytopenia in cirrhosis[37]. 
In conclusion, platelet-to-lymphocyte ratio is an 
easy and cheap value to use for selecting patients with 
hepatocellular cancer waiting for liver transplantation. 
A direct correlation between PLR values and tumor 
aggressiveness has been observed in several studies. 
High pre-transplant PLR values cause a 3.3-fold 
increased risk for post-transplant recurrence. More 
studies aimed at better understanding biological and 
clinical mechanisms of the link between PLR and HCC 
are needed.  
ARTICLE HIgHLIgHTS
Research background
Liver transplantation is the best curative therapy in case of hepatocellular 
cancer (HCC). However, it represents a scarce resource due to the reduced 
number of donors. Thus, a careful selection of HCC patients must be done 
preoperatively, with the intent to minimize the risk of futile transplants (i.e., 
post-operative cancer recurrence). As a consequence, new and easy-to-use 
predictors of recurrence are needed. 
Research motivation
Recently, several biological aspects of HCC have been investigated, with 
the intent to identify scores aimed at improving the prediction of poor post-
transplant outcomes. Among them, the inflammatory marker platelet-to-
lymphocyte ratio (PLR) has been only marginally investigated, although it 
should represent a potentially excellent and cheap marker to use. 
Research objectives
The main objective of the present study is to evaluate the role of PLR as a 
possible selection tool for the risk of HCC recurrence in the setting of liver 
transplantation. 
Research methods
A systematic review and a meta-analysis have been performed with the intent 
to evaluate the role of PLR. The PRISMA Guidelines have been used for 
performing the systematic research of studies focused on PLR, HCC and LT. 
Research results
Five articles coming from Europe and Asia have been identified, with a total of 
899 subjects investigated. At meta-analysis, high PLR value was associated 
with a significant increase in recurrence after transplantation (OR = 3.33; 
95%CI: 1.78-6.25; p < 0.001). 
Research conclusions
A direct correlation between PLR values and tumor aggressiveness has been 
observed. High pre-transplant PLR values cause a 3.3-fold increased risk for 
post-transplant recurrence. Platelet-to-lymphocyte ratio is an easy and cheap 
value to use for selecting patients with hepatocellular cancer waiting for liver 
transplantation. PLR should be taken into account in the creation of new 
selection scores for HCC.  
Research perspectives
More studies aimed at better understanding biological and clinical mechanisms 
of the link between PLR and HCC are necessary.  
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